Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1
(2013)
Journal Article
Seedhouse, C., Mills, K. I., Ahluwalia, S., Grundy, M., Shang, S., Burnett, A. K., …Pallis, M. (2014). Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1. Leukemia Research, 38(1), 131-137. https://doi.org/10.1016/j.leukres.2013.10.030
CLAIRE SEEDHOUSE's Outputs (3)
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells (2013)
Journal Article
Pallis, M., Burrows, F., Whittall, A., Boddy, N., Seedhouse, C., & Russell, N. (2013). Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC Pharmacology and Toxicology, 14(June), Article 11. https://doi.org/10.1186/2050-6511-14-32Background
Dormant cells are characterised by low RNA synthesis. In contrast, cancer cells can be addicted to high RNA synthesis, including synthesis of survival molecules. We hypothesised that dormant cancer cells, already low in RNA, might be sens... Read More about Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells (2013)
Journal Article
Sultana, R., Abdel-Fatah, T., Perry, C., Moseley, P., Albarakti, N., Mohan, V., …Madhusudan, S. (2013). Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PLoS ONE, 8(2), Article e57098. https://doi.org/10.1371/journal.pone.0057098Introduction
Ataxia telangiectasia mutated and Rad3 Related (ATR) protein kinase is a key sensor of single-stranded DNA associated with stalled replication forks and repair intermediates generated during DNA repair. XRCC1 is a critical enzyme in sin... Read More about Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.